Pharma market

801 views
751 views

Published on

Current scenario of Indian pharma market

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
801
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
46
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Pharma market

  1. 1. PHARMA <ul><li>By </li></ul><ul><li>Deepak sahu </li></ul>
  2. 6. The Indian Patent Act <ul><li>The Indian Patent Act,1970 </li></ul><ul><ul><li>Process Patent </li></ul></ul><ul><ul><li>5 yrs. for Food, Drugs, Medicines, etc. & 14 yrs. for other inventions </li></ul></ul><ul><ul><li>Indian Market became undesirable to the MPCs </li></ul></ul><ul><ul><li>Focus on Generics and Neglect of New Drug Discovery </li></ul></ul><ul><ul><li>Development of Expertise in Reverse Engineering </li></ul></ul><ul><li>The Patent (Amendment) Act, 2005 </li></ul><ul><ul><li>Product Patent </li></ul></ul><ul><ul><li>20 yrs. for all inventions </li></ul></ul><ul><ul><li>Reversal of Law in case of violation of Patent from Plaintiff to Defendant </li></ul></ul><ul><ul><li>To recognize all patents filed after 1/1/05 </li></ul></ul><ul><ul><li>MPCs to enjoy same IPR in India as they enjoyed elsewhere </li></ul></ul><ul><ul><li>Shifting of focus from Generics to Innovative Drug Discovery </li></ul></ul>
  3. 7. GROWTH ENABLERS IPR ENFORCEMENT Accelerating Clinical Trials Increasing M&A Off shoring of R&D Activities Proven Prowess In Data Management Regulatory Reforms Fiscal Reforms
  4. 8. <ul><li>Off shoring of R&D Activities </li></ul><ul><li>Recognition of R&D as important growth driver by Indian companies </li></ul><ul><li>Increase in Investment in R&D Activities from 4% in 2004-05 to 7.7% in </li></ul><ul><li>2005-06 as a percentage of Sales </li></ul><ul><li>Low cost of doing R&D in India </li></ul><ul><li>Fiscal Reforms </li></ul><ul><li>Conferred Tax Deduction for expenses related to R&D </li></ul><ul><li>Reduced Interest Rates for Export financing </li></ul><ul><li>Reduction in Import Duties </li></ul><ul><li>Favorable economic environment for FDI in R&D </li></ul>
  5. 10. <ul><li>Accelerating Clinical Trials </li></ul><ul><li>Bridge between New Drug Discovery and New Drug Approval </li></ul><ul><li>Alone accounts for over 50% of the overall budget for the new </li></ul><ul><li>drug development </li></ul><ul><li>Large Patients pool with genetic diversity </li></ul><ul><li>Lower per patient cost of conducting trial in India </li></ul><ul><li>Clinical Research Outsourcing (CRO) Market stands at around Rs. 300 </li></ul><ul><li>crore and growing at 30% annually </li></ul><ul><li>Proven Prowess in Chemistry and Data Management </li></ul><ul><li>Abundance of highly trained and technically skilled clinical research </li></ul><ul><li>and medical professionals </li></ul><ul><li>Strong domestic capabilities in Data Management and IT </li></ul>
  6. 11. The Entry into Market
  7. 12. <ul><li>Increasing Mergers & Acquisitions </li></ul><ul><li>Rush of International Acquisitions by leading Indian Pharmaceutical Firms </li></ul><ul><li>Acquisitions intended to give Indian Drug Firms wide geographical </li></ul><ul><li>footprints </li></ul><ul><li>Some of the key acquisitions include (1) Dr. Reddy’s acquiring Betapharm, </li></ul><ul><li>a large German Generic player, & (2) Ranbaxy acquiring Terapia, largest </li></ul><ul><li>Generic company in Romania </li></ul><ul><li>Regulatory Reforms </li></ul><ul><li>Strengthening of Legal framework to curb production of spurious drugs </li></ul><ul><li>Formation of centralized National Drug Authority (NDA) </li></ul>
  8. 13. Future Outlook & Challenges <ul><li>Emergence of India as leading country in Global Pharmaceutical Market </li></ul><ul><li>Export to be the major thrust of the Industry </li></ul><ul><li>Evolving of Bio-pharmaceutical Market likely to emerge as one of the largest producer of Vaccines </li></ul><ul><li>Biotech Market estimated to reach $5 billion by 2010 </li></ul><ul><li>More Investment required in R&D </li></ul><ul><li>Fiscal Incentives for R&D should be provided on a long term basis of around 10 years </li></ul><ul><li>Clear Guidelines required on OTC Drugs </li></ul><ul><li>Higher Budget Outlay for Healthcare Services required </li></ul>
  9. 14. Thank You

×